[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"brain-arterial-disease\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:brain-arterial-disease":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,48,83],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":32,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100433671","safety-performance-and-usability-of-balt-medical-devices-the-evidence-post-marketing-clinical-follow-up-platform-100433671",false,"NCT04927156","Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform","Safety, Performance and Usability of BALT Medical Devices: The EVIDENCE Post Marketing Clinical Follow-up Platform. An International, Multicenter, Prospective, and Retrospective Data Collection","EVIDENCE","Inclusion Criteria:\n\n* Provision of a signed, written and dated informed consent or non-opposition (where applicable)\n\nExclusion Criteria\n\n* Device(s) used in multiple procedures (two, or more, pathologies treated during the same procedure)\n* Contra-indications of each device as described in the instructions for use.","ALL","2 Years",{"count":20,"type":21},10000,"ESTIMATED","OBSERVATIONAL","BALT has designed an electronic platform to continue collecting clinical data as part of the post-marketing clinical follow-up of its devices.\n\nThis platform is purely exploratory, without hierarchical order of the objectives and associated outcomes.",[25,26,27,28,29,30,31],"Intracranial Aneurysm","Brain Arterial Disease","Acute Ischemic Stroke","Peripheral Vascular Diseases","AVM - Cerebral Arteriovenous Malformation","AVM","Fistulas Arteriovenous",[33,34],"catheter","guidewire","RECRUITING","2025-09-16",{"date":38,"type":39},"2025-09-18","ACTUAL",{"date":41,"type":39},"2021-07-12",{"date":43,"type":21},"2041-10",{"name":45,"class":46},"Balt Extrusion","INDUSTRY",12,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":52,"acronym":4,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":57,"conditions":58,"keywords":64,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":75,"completionDateStruct":77,"leadSponsor":79,"locationsCount":82},"100602692","a-vision-language-foundation-model-for-brain-disease-diagnosis-from-multimodal-data-100602692","NCT07126821","A Vision-Language Foundation Model for Brain Disease Diagnosis From Multimodal Data","Inclusion Criteria:\n\nPatients with brain diseases:\n\n* Patients with brain tumors were pathologically diagnosed.\n* Patients with other brain diseases were correctly diagnosed.\n* The clinical case data of all patients were complete.\n\nNon-brain disease population:\n\n* All patients have complete clinical case data, complete brain MRI, no history brain diseases, no brain surgery or other brain diseases that affect the diagnosis and observation of MR imaging.\n\nExclusion Criteria:\n\n* Cases in which MRI were incomplete or with significant noise and artifacts.",true,{"count":56,"type":21},100000,"The goal of this observational study is to develop an innovative, comprehensive, and explainable AI vision-language foundation model (VLM) to advance the diagnosis and interpretation of brain diseases using multi-modal data. We will include patient demographics, medical imaging data (such as MRI, CT, and PET scans), histopathological data, genomic data when available, and other necessary laboratory examinations and tests to establish a screening and diagnostic model for brain diseases.",[59,26,60,61,62,63],"Brain (Nervous System) Cancers","Neuro-Degenerative Disease","Brain Tumors","Brain Diseases","Neurological di",[65,66,67,68,69,70,71],"brain tumors","brain cancers","brain diseases","foundation model","diagnosis","prediction","neurological diseases","2025-08-15",{"date":74,"type":39},"2025-08-17",{"date":76,"type":39},"2025-05-15",{"date":78,"type":21},"2030-12-31",{"name":80,"class":81},"Xiangya Hospital of Central South University","OTHER",1,{"id":84,"slug":85,"hasResults":11,"nctId":86,"briefTitle":87,"officialTitle":88,"acronym":89,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":17,"minAge":91,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":94,"conditions":95,"keywords":96,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":102,"completionDateStruct":104,"leadSponsor":106,"locationsCount":82},"100554074","liquid-biopsies-for-the-detection-of-somatic-mutations-in-bavms-100554074","NCT06494358","Liquid Biopsies for the Detection of Somatic Mutations in bAVMs","Liquid Biopsies for the Detection of Somatic Mutations in Brain Arteriovenous Malformations","BioMAV","\"\\_Age ≥ 18 years\n\n* Treated for bAVM at Pitié-Salpêtrière Hospital\n* Indication for treatment by embolization followed by surgery decided in a multidisciplinary consultation meeting (RCP) at Pitié-Salpêtrière Hospital\n* Treatment by embolization possibly followed by surgery within 24-48 hours if the embolization is incomplete\n* Informed about the study and not objecting to participation\"\n\nExclusion criteria :\n\n* Extra-cerebral arteriovenous malformations\n* Under legal protection (guardianship\u002Fcurators, etc.)\n* Pregnancy\n* Not eligible for combined treatment (embolization followed by surgery)","18 Years",{"count":93,"type":21},50,"\"Personalized medicine has revolutionized patient care, particularly in oncology. Brain arteriovenous malformations (bAVMs) are abnormal vessels located on the surface of the brain or within the brain parenchyma, causing abnormal communication between arterial and venous networks, without the interposition of the capillary bed. The main risk of these malformations is rupture, leading to intracranial bleeding, which can cause severe sequelae or even death. bAVMs (except those of clearly identified genetic origin \\[\\\u003C 5%\\], such as mutations associated with Rendu-Osler disease) have long been considered non-genetic in origin.\n\nHowever, somatic genetic mutations activating the RAS\u002FRAF\u002FMEK\u002FERK (MAPK) signaling pathway have recently been identified in surgical specimens of bAVMs. Additionally, targeted inhibition of this pathway is effective in treating these malformations in animals and appears to be effective in extracranial arteriovenous malformations, particularly superficial ones.\n\nNext-generation sequencing of circulating DNA on liquid biopsies is a promising and minimally invasive approach to studying the presence of mutations in arteriovenous malformations.\n\nThe treatment of a bAVM aims to obliterate the malformation to prevent or avoid the risk of hemorrhage. It may involve several therapeutic modalities: microsurgery, endovascular embolization, and radiosurgery. These treatments can be combined, and microsurgery is often preceded by pre-surgical embolization, aimed at reducing the hemorrhagic risk of the intervention. However, these are invasive treatments, not without risk.\n\nThe identification of mutations through liquid biopsies could enable the development of non-invasive targeted therapies against these bAVMs.\n\nThis research aims to identify somatic genetic mutations activating the MAPK signaling pathway in bAVMs. These mutations have already been identified in surgical specimens. This research aims to evaluate the diagnostic performances of liquid biopsies (detection of genetic mutations in blood samples, i.e., circulating DNA), with the gold standard being the detection of the same mutations in surgical specimens.\"",[26],[97,98],"brain arteriovenous malformation","liquid biopsies","2025-05-14",{"date":101,"type":39},"2025-05-16",{"date":103,"type":39},"2025-04-01",{"date":105,"type":21},"2026-12-01",{"name":107,"class":81},"Assistance Publique - Hôpitaux de Paris"]